This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

2014 FDA Drug Approval Decision Calendar

Updated as of Jan. 6, 2014.

For your biotech trading adventures in the new year -- an FDA drug approval calendar for 2014.

The following calendar includes 34 FDA drug approval decisions and scheduled advisory panels from December 2013 through October 2014. I compiled the calendar using company reports, my own research and the remarkably useful services of


January 2014: Drug approval decisions

Bristol-Myers Squibb 
Dapagliflozin for Type 2 diabetes
Jan. 14

Vanda Pharmaceuticals  (VNDA)
Hetlioz for non-24 sleep disorder
Jan. 31

FDA advisory panels:

Chelsea Therapeutics (CHTP) 
Northera for orthostatic hypotension
Jan. 14

February 2014: Drug approval decisions

Chelsea Therapeutics
Northera for orthostatic hypotension
Feb. 14

Bristol-Myers Squibb
Metreleptin for lipodystrophy
Feb. 27

Biomarin  (BMRN)
Vimizim for morquio syndrome
Feb. 28

Pharmacyclics  (PCYC) and Johnson & Johnson  (JNJ)
Imbruvica for chronic lymphocytic leukemia
Feb. 28

March 2014: Drug approval decisions

Celgene  (CELG)
Apremilast for psoriatic arthritis
March 21

April 2014: Drug approval decisions

Biogen Idec
Alprolix for hemophilia B 
Jan. 3

MannKind  (MNKD)
Afrezza for Type 1 and 2 diabetes
April 15

GlaxoSmithKline  (GSK)
Abiglutide for diabetes
April 15

Santarus  (SNTS)
Ruconest for hereditary angioedema
April 16

Pozen (POZN)
PA32540 & PA8140 for heart disease 
Jan. 24

Click ahead for more FDA drug approval decision dates

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,879.74 +51.99 0.29%
S&P 500 2,072.99 +0.16 0.01%
NASDAQ 4,805.8940 +18.5770 0.39%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs